To kick things off, we'll set the stage on what defines non-muscle invasive bladder cancer and how we triage patient ...

Dubai: A 53-year-old Pakistani expat in the UAE has made an extraordinary recovery after surviving a catastrophic heart ...

A 53-year-old Pakistani businessman in Dubai has defied the odds by surviving a life-threatening heart rupture, thanks to the ...

ImmunityBio offers significant upside despite ongoing dilution and cash burn concerns. Click here to read an analysis of IBRX ...

CG Oncology stands out with strong phase 3 data and a robust pipeline in bladder cancer. Click here to read my most recent ...

In September 2025, the U.S. Food and Drug Administration (FDA) approved several new cancer therapies and supportive care ...

We recently compiled a list of the 12 Healthcare Stocks with Insider Buying in 2025. ImmunityBio, Inc. is one of them.

A novel drug-delivery system has demonstrated effectiveness in treating specific bladder cancer patients whose tumors ...

The FDA in September issued two rejections for spinal muscular atrophy therapies—both linked to manufacturing problems—and ...

In 2025, there will be a complicated combination of opportunities and difficulties in the healthcare innovation landscape, ...

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today reported the grant of inducement equity ...